Clinical Evidence on GLP-1 Receptor Agonist Safety and Effectiveness
GLP-1 receptor agonist safety and efficacy are supported by expert consensus and clinical trials. These agents provide meaningful cardiovascular risk reduction and weight management benefits. Family medicine clinicians can confidently discuss these…
Tirzepatide Clinical Research: Lilly’s Oral Obesity Pill and Heart Data
Oral tirzepatide obesity pill represents a significant advancement in GLP-1 therapy for obesity management. Clinical research from Lilly highlights its potential cardiovascular benefits. This emerging oral option may improve patient adherence and expand…
GLP-1 Weekly Roundup April 16, 2026: Liver Benefits and Research
New research highlights GLP-1 receptor agonist liver benefits alongside diabetes prevention with metformin. Genetic predictors of weight loss response enhance personalized treatment. This April 2026 roundup covers key clinical evidence for GLP-1…
GLP-1 Digest: Latest Research and Clinical Updates April 16,
This issue highlights GLP-1 receptor agonists liver benefits with new research supporting their role in metabolic medicine. Genetic predictors of treatment response and metformin's role in insulin resistance are also discussed. These findings offer…
GLP-1 Policy Watch: Insurance, Compounding, and FDA Updates
The GLP-1 insurance coverage update highlights key policy developments impacting clinical prescribing and patient access. Twelve states mandate coverage for obesity, but restrictions remain. Clinicians must verify formulary status to navigate insurance…
Losing Weight on GLP-1s? Protect Your Muscle Along the Way
GLP-1 muscle preservation is essential during weight loss to avoid losing lean muscle mass. Pairing GLP-1 medications with adequate protein intake and resistance exercise helps protect muscle. Consult your doctor for a plan focused on muscle preservation…
Your Body Fights Back When You Stop GLP-1 Medications
Clinical Takeaway When GLP-1 therapy stops, hunger hormones rebound, gastric emptying speeds up, and appetite signaling in the brain returns to its previous baseline, often triggering rapid weight regain. This is not a willpower failure but a predictable…
GLP-1 Receptor Agonist Benefits for Liver Health: New Evidence
Recent studies reveal that GLP-1 receptor agonist shows liver benefits in new research, demonstrating direct effects on hepatic inflammation and fat reduction. These benefits occur independently of weight loss, expanding treatment options for metabolic…
GLP-1 Receptor Agonist Shows Liver Benefits in New Research
GLP-1 receptor agonist benefits for liver health are increasingly recognized beyond weight loss effects. New research highlights direct hepatic advantages in metabolic liver disease. These findings may influence treatment approaches for patients with…
Metformin & Insulin Resistance: Evidence for Diabetes Prevention
Metformin diabetes prevention evidence highlights its benefit in patients with severe insulin resistance. This targeted approach improves outcomes in high-risk prediabetes populations. Understanding insulin resistance helps optimize diabetes prevention…